ALK and non-small cell lung carcinoma: At the time of this publication, alkotinib (ZG-0148), another multi-kinase inhibitor with demonstrated activity against ALK and ROS1 gene rearrangements, is undergoing evaluation in a phase 2 clinical trial involving patients with ALK-positive NSCLC previously treated with crizotinib (NCT04211922).